Negus S Stevens, Marsh S A, Townsend E A
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, United States.
Front Pharmacol. 2021 Jan 29;11:615782. doi: 10.3389/fphar.2020.615782. eCollection 2020.
Clinically relevant chronic pain is often associated with functional impairment and behavioral depression as an "affective/motivational" sign of pain; however preclinical animal models of inflammatory and neuropathic pain often produce weak evidence of impaired function. We hypothesized that hindpaw mechanical stimulation produced by a requirement to rear on a textured "NOX" plate would punish operant responding in rats treated with intraplantar complete Freund's adjuvant (CFA, a model of inflammatory pain) or the chemotherapeutic paclitaxel (PTX, a model of neuropathic pain) and produce sustained pain-related depression of operant behavior. Male Sprague-Dawley rats were trained under a progressive-ratio (PR) schedule of food-maintained operant responding, then treated with CFA (100 µL in left hindpaw), PTX (2.0 mg/kg IP on alternate days for four total injections; 6.6 mg/kg IV on alternate days for three total injections), or saline vehicle. PR break points and mechanical thresholds for paw withdrawal from von Frey filaments were then tracked for 28 days. Subsequently, rats were tested with the opioid receptor antagonist naltrexone to assess latent sensitization and with the kappa opioid receptor (KOR) agonist U69593 to assess KOR function. CFA produced significant mechanical hypersensitivity for 3 weeks but decreased PR breakpoints for only 1 day. Both IP and IV PTX produced mechanical hypersensitivity for at least three weeks; however, only IV PTX decreased PR breakpoints, and this decrease was not alleviated by morphine. After recovery, naltrexone reinstated mechanical hypersensitivity in CFA- but not PTX-treated rats, and it did not reinstate depression of breakpoints in any group. U69593 dose-dependently decreased PR breakpoints in all groups with no difference between control vs. CFA/PTX groups. These results suggest that rearing on a textured NOX plate was not sufficient to punish operant responding in CFA- and PTX-treated rats despite the presence of sustained mechanical hypersensitivity. The rapid recovery of operant responding could not be attributed to latent sensitization, KOR downregulation, or behavioral tolerance. These results extend the range of conditions under which putative chronic pain manipulations produce weak evidence for depression of operant responding as a sign of the "affective/motivational" component of pain in rats.
临床上相关的慢性疼痛通常与功能障碍和行为抑郁相关,后者是疼痛的一种“情感/动机”表现;然而,炎症性疼痛和神经性疼痛的临床前动物模型往往只能提供功能受损的微弱证据。我们假设,在有纹理的“NOX”板上后肢站立所产生的后爪机械刺激,会惩罚经足底注射完全弗氏佐剂(CFA,一种炎症性疼痛模型)或化疗药物紫杉醇(PTX,一种神经性疼痛模型)处理的大鼠的操作性反应,并导致与疼痛相关的操作性行为持续抑郁。雄性Sprague-Dawley大鼠在以食物维持的操作性反应的渐进比率(PR)时间表下接受训练,然后分别用CFA(左后爪注射100µL)、PTX(2.0mg/kg腹腔注射,隔天一次,共注射四次;6.6mg/kg静脉注射,隔天一次,共注射三次)或生理盐水载体进行处理。然后追踪PR断点和用von Frey细丝刺激后爪撤回的机械阈值,持续28天。随后,用阿片受体拮抗剂纳曲酮对大鼠进行测试,以评估潜在的敏化作用,并用κ阿片受体(KOR)激动剂U69593评估KOR功能。CFA产生了持续3周的显著机械性超敏反应,但仅在1天内降低了PR断点。腹腔注射和静脉注射PTX均产生了至少3周的机械性超敏反应;然而,只有静脉注射PTX降低了PR断点,且这种降低并未被吗啡缓解。恢复后,纳曲酮使CFA处理的大鼠恢复了机械性超敏反应,但未使PTX处理的大鼠恢复;并且它没有使任何一组的断点抑郁恢复。U69593剂量依赖性地降低了所有组的PR断点,对照组与CFA/PTX组之间无差异。这些结果表明,尽管存在持续的机械性超敏反应,但在有纹理的NOX板上后肢站立不足以惩罚CFA和PTX处理的大鼠的操作性反应。操作性反应的快速恢复不能归因于潜在的敏化作用、KOR下调或行为耐受性。这些结果扩展了假定的慢性疼痛操作产生微弱证据表明操作性反应抑郁作为大鼠疼痛“情感/动机”成分标志的条件范围。